Nanovery, a Newcastle-based biotech firm, joined the Earlymarket portfolio in 2021. Focused on developing nanorobot technology to diagnose deadly diseases at an earlier stage, they have just completed a successful trial with NHS scientists. The findings demonstrated the Nanovery technology achieved the same level of accuracy as established methods but in a more timely and cost-efficient manner.
The successful results are a major milestone for Nanovery. The news comes shortly after Nanovery completed its latest funding round, raising £1.85 million from a group of investors that includes leading venture capital firms and angel investors. The new funding will help the company accelerate the development and commercialisation of its technology.
Founder of Nanovery, Jurek Kozyra, added, “The work we have done with the Newcastle team has proven the effectiveness of the technology we developed. We are grateful for their support during the testing phase. We now move to the next stage of validation and commercialisation.”
The successful results are a major milestone for Nanovery. The news comes shortly after Nanovery completed its latest funding round, raising £1.85 million from a group of investors that includes leading venture capital firms and angel investors. The new funding will help the company accelerate the development and commercialisation of its technology.
Founder of Nanovery, Jurek Kozyra, added, “The work we have done with the Newcastle team has proven the effectiveness of the technology we developed. We are grateful for their support during the testing phase. We now move to the next stage of validation and commercialisation.”